# A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects

> **NCT02562950** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG1837 500 mg
- **DRUG:** Midazolam
- **DRUG:** GLPG1837 1000 mg

## Key facts

- **NCT ID:** NCT02562950
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562950, "A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02562950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*